Ignite Creation Date:
2024-05-06 @ 10:12 AM
Last Modification Date:
2024-10-26 @ 12:26 PM
Study NCT ID:
NCT03197298
Status:
COMPLETED
Last Update Posted:
2017-06-23
First Post:
2017-05-23
Brief Title:
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Sponsor:
Thorax Centrum Twente
Organization:
Thorax Centrum Twente
Study Overview
Official Title:
Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents CHANGE DAPT
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHANGE DAPT
Brief Summary:
Acute coronary syndrome ACS guidelines have been changed favoring dual antiplatelet therapy DAPT with the more potent P2Y12 inhibitor ticagrelor over clopidogrel besides aspirin This change is based on studies that showed benefits of ticagrelor However study participants were only partly treated by percutaneous coronary intervention PCI In patients who were treated by PCI this was generally performed using of bare metal or first-generation drug-eluting stents DES
CHANGE DAPT is an investigator-initiated prospective single centre registry in which we evaluate the impact of the guideline suggested change in the primary DAPT regimen from clopidogrel to ticagrelor on 1-year clinical outcome in ACS patients treated by PCI with newer-generation DES in the Thoraxcentrum Twente
CHANGE DAPT is an investigator-initiated prospective single centre registry in which we evaluate the impact of the guideline suggested change in the primary DAPT regimen from clopidogrel to ticagrelor on 1-year clinical outcome in ACS patients treated by PCI with newer-generation DES in the Thoraxcentrum Twente
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None